Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.advisor | Dana Kigitoviča | - |
dc.contributor.author | Louis Tom Bolte | - |
dc.contributor.other | Medicīnas fakultāte | lv-LV |
dc.contributor.other | Faculty of Medicine | en-UK |
dc.date.accessioned | 2023-04-14T21:15:55Z | - |
dc.date.available | 2023-04-14T21:15:55Z | - |
dc.date.issued | 2022 | - |
dc.identifier.uri | https://dspace.rsu.lv/jspui/handle/123456789/11683 | - |
dc.description | Medicīna | lv-LV |
dc.description | Medicine | en-UK |
dc.description | Veselības aprūpe | lv-LV |
dc.description | Health Care | en-UK |
dc.description.abstract | Šis ir klīnisks gadījuma ziņojums par pacientu ar hronisku nieru slimību beigu stadijā, kas attīstās sekundāri ar c-ANCA saistītam vaskulītam. Pirms ar c-ANCA saistīta vaskulīta attīstīšanas pacientam bija pastāvīga priekškambaru mirdzēšana un viņš saņēma insulta profilakses dabigatrānu. Tā kā pacientam bija hroniska nieru slimība beigu stadijā, insulta profilakse tika mainīta uz varfarīnu, tomēr pacients izrādījās rezistents pret to. Tāpēc ziņojumā ir aplūkoti dažādi varianti, kā šādu pacientu varētu alternatīvi antikoagulēt. Turklāt šajā gadījuma ziņojumā ir aplūkota pacientu ārstēšana ar c-ANCA saistītu vaskulītu (pazīstams arī kā granulomatoze ar poliangiītu) ar smagu nieru un plaušu iesaistīšanos. | lv-LV |
dc.description.abstract | This is a clinical case report about a patient with end-stage chronic kidney disease developing secondary to c-ANCA-associated vasculitis. Prior to developing c-ANCA associated vasculitis, the patient had permanent atrial fibrillation and received for stroke prevention dabigatran. Due to the patient having end-stage chronic kidney disease, the stroke prophylaxis was changed to warfarin, however, the patient proved resistant to it. Therefore, in the case report are different options discussed, as to how such a patient could be anticoagulated alternatively. Additionally, this case report discusses the management of patients with c-ANCA associated vasculitis (also known as granulomatosis with polyangiitis) with severe renal and pulmonary involvement. | en-UK |
dc.language.iso | en-UK | - |
dc.publisher | Rīgas Stradiņa universitāte | lv-LV |
dc.publisher | Rīga Stradiņš University | en-UK |
dc.rights | info:eu-repo/semantics/restrictedAccess | - |
dc.subject | Hroniska nieru slimība | lv-LV |
dc.subject | HNS | lv-LV |
dc.subject | priekškambaru fibrilācija | lv-LV |
dc.subject | c-ANCA-asociēts vaskulīts | lv-LV |
dc.subject | granulomatozi ar poliangiītu | lv-LV |
dc.subject | antikoagulants | lv-LV |
dc.subject | tiešais perorālais antikoagulants | lv-LV |
dc.subject | apiksabāns | lv-LV |
dc.subject | rivaroksabāns | lv-LV |
dc.subject | varfarīns | lv-LV |
dc.subject | LMWH | lv-LV |
dc.subject | gadījumu apraksts | lv-LV |
dc.subject | Chronic kidney disease | en-UK |
dc.subject | CKD | en-UK |
dc.subject | atrial fibrillation | en-UK |
dc.subject | AF | en-UK |
dc.subject | c-ANCA-associated vasculitis | en-UK |
dc.subject | granulomatosis with polyangiitis | en-UK |
dc.subject | anticoagulant | en-UK |
dc.subject | direct oral anticoagulant (DOAC) | en-UK |
dc.subject | apixaban | en-UK |
dc.subject | rivaroxaban | en-UK |
dc.subject | warfarin | en-UK |
dc.subject | LMWH | en-UK |
dc.subject | case report | en-UK |
dc.title | Anticoagulation in Concomittant Chronic Kidney Disease and Atrial Fibrillation: A Case Report | en-UK |
dc.title.alternative | Antikoagulācija pacientam ar hronisku nieru slimību un ātriju fibrilācija: klīniskais gadījums | lv-LV |
dc.type | info:eu-repo/semantics/other | en-UK |
Appears in Collections: | Studējošo pētnieciskie darbi |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
Medicinas_fakultate_SSNMFz_2022_Louis_Tom_Bolte_031431.pdf | Studējošā pētnieciskais darbs | 404.58 kB | Adobe PDF | View/Open Request a copy |
Signed declaration for research paper.pdf | Noslēguma darba pielikums | 373.08 kB | Adobe PDF | View/Open Request a copy |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.